Extracellular
metalloproteinase inducer (
EMMPRIN) and a
disintegrin and
metalloproteinase (ADAM12) play a major role in
cancer invasion and
metastasis owing to the fact that they are directly related to the cell microenvironment and extracellular matrix (ECM) degradation. The aim of this study was to search for an answer to the question "whether the determination of
EMMPRIN and ADAM12 values especially in urine may be helpful for the early diagnosis of
prostate cancer without employing invasive methods" and also to check whether they may be useful for the determination of the patients with high
metastasis risk. Peripheral blood and urine from 66
prostate cancer patients (40 local, 20 locally advanced, 6 metastatic) and 14 healthy controls were evaluated by
enzyme-linked
immunosorbent assay (ELISA) method. Serum
EMMPRIN and ADAM12 values of the patients were seen to be statistically higher than the serum
EMMPRIN and ADAM12 values of the healthy controls (p=0.01 and p=0.001, respectively). The urine ADAM12 levels were significantly higher in patients (p=0.013). No significant relationships were found between urine
EMMPRIN values of the patients and the healthy controls (p>0.05). Positive correlation between urine
EMMPRIN-urine ADAM12 tests was found in total patients group (r=0.683, p=0.001). Our preliminary results revealed that serum
EMMPRIN and ADAM12 values and urine ADAM12 values may be useful markers in
prostate cancer therapy. Due to the high correlation between these two tests, we are of the opinion that the use of urine ADAM12 in clinic may be sufficient and favorable together with
prostate-specific antigen (PSA) for treatment.